IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A polypeptide compound of the following general formula (I):



(I)

wherein

R^1 is hydrogen or acyl group,

R^2 is hydrogen or acyl group,

R^3 is lower alkyl which has one or more hydroxy or protected hydroxy,

R^4 is hydrogen or hydroxy,

R^5 is hydrogen, hydroxy, lower alkoxy or hydroxysulfonyloxy, and

R^6 is hydroxy or acyloxy,

or a salt thereof.

Claim 2 (Currently Amended): [[A]] The compound of claim 1, wherein

R^1 is hydrogen, lower alkoxycarbonyl, higher alkanoyl or benzoyl substituted with one or more suitable substituent(s),

R^2 is hydrogen,

R^3 is lower alkyl which has one or more hydroxy,

R^4 is hydrogen or hydroxy,

R^5 is hydroxy or hydroxysulfonyloxy and

R^6 is hydroxy.

Claim 3 (Currently Amended): [[A]] The compound of claim 2, wherein

R^1 is hydrogen, lower alkoxycarbonyl, higher alkanoyl or benzoyl substituted with one or more suitable substituent(s),

R^2 is hydrogen,

R^3 is lower alkyl which has two hydroxy,

R^4 is hydrogen or hydroxy;

R^5 is hydroxy or hydroxysulfonyloxy; and

R^6 is hydroxy.

Claim 4 (Currently Amended): [[A]] The compound of claim 3, wherein

R^1 is benzoyl substituted with a suitable substituent selected from the group consisting of

thiadiazolyl substituted with phenyl having phenyl substituted with morphlino having lower alkyl,

thiadiazolyl substituted with phenyl having a suitable substituent selected from the group consisting of lower alkoxy(lower)alkoxy and lower alkoxy(higher)alkoxy,

piperazinyl substituted with phenyl having piperidyl substituted with a suitable substituent selected from the group consisting of phenyl having lower alkoxy(lower)alkoxy, cyclo(lower)alkyloxy and lower alkoxy(lower)alkylthio,

piperazinyl substituted with phenyl having phenyl substituted with morpholino having lower alkyl,

imidazothiadiazolyl substituted with phenyl having piperidyl substituted with a suitable substituent selected from the group consisting of lower alkoxy(lower)alkoxy and lower alkoxy(lower)alkylthio,

imidazothiadiazolyl substituted with phenyl having lower alkoxy(lower)alkoxy,

phenyl substituted with piperazinyl having phenyl substituted with morpholino having lower alkyl,

isoxazolyl substituted with phenyl having lower alkoxy(lower)alkoxy,

isoxazolyl substituted with phenyl having higher alkoxy substituted with morpholino having lower alkyl,

thiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl which has one or more suitable substituent(s) selected from the group consisting of lower alkyl, lower alkenyl, lower alkoxy(higher)alkoxy and phenyl,

thiadiazolyl substituted with phenyl having piperazinyl substituted with lower alkyl having cyclo(lower)alkyl,

thiadiazolyl substituted with phenyl having piperidyl substituted with one or more suitable substituent(s) selected from the group consisting of cyclo(lower)alkyloxy, lower alkoxy(lower)alkoxy and lower alkoxy(lower)alkoxy(lower)alkyl,

thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl and lower alkoxy,

thiadiazolyl substituted with pyridyl having piperazinyl substituted with cyclo(lower)alkyl having lower alkyl,

imidazothiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl,

imidazothiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl having lower alkyl, and

phenyl substituted with piperazinyl having cyclo(lower)alkyl substituted with one or more suitable substituent(s) selected from the group consisting of cyclo(lower)alkyl which may have lower alkoxy, lower alkyl, lower alkoxy and phenyl which may have lower alkoxy,

R^2 is hydrogen,

R^3 is lower alkyl which has two hydroxy,

R^4 is hydrogen or hydroxy;

R^5 is hydroxy or hydroxysulfonyloxy; and

R^6 is hydroxy.

Claim 5 (Currently Amended): [[A]] The compound of the claim 4, wherein

R^1 is benzoyl which has thiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl which has lower alkyl,

benzoyl which has thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyloxy,

benzoyl which has phenyl substituted with piperazinyl having cyclo(lower)alkyl substituted with cyclo(lower)alkyl and lower alkoxy, or

benzoyl which has thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl,

R^2 is hydrogen,

R^3 is lower alkyl which has two hydroxy,

R^4 is hydrogen or hydroxy;

R^5 is hydroxy or hydroxysulfonyloxy; and

R^6 is hydroxy.

Claims 6-12 (Canceled).

Claim 13 (New): The compound of claim 4, wherein

R^1 is benzoyl which has thiadiazolyl substituted with phenyl having a suitable substituent selected from the group consisting of

(1) piperazinyl substituted with cyclo(lower)alkyl which has lower alkyl, and

(2) piperidyl substituted with cyclo(lower)alkyl and (lower)alkoxy,

R^2 is hydrogen,

R^3 is lower alkyl which has two hydroxyl,

R^4 is hydrogen,

R^5 is hydroxysulfonyloxy, and

R^6 is hydroxyl.

Claim 14 (New): The compound of claim 13, wherein

R^1 is 4-[5-[4-[cis-4-(4-methylcyclohexyl)-piperazin-1-yl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyl,

R^2 is hydrogen,

R^3 is 2-hydroxy-1-(hydroxymethyl)ethyl,

R^4 is hydrogen,

R^5 is hydroxysulfonyloxy, and

R^6 is hydroxyl.

Claim 15 (New): The compound of claim 13, wherein

R^1 is 4-[5-[4-(4-methoxy-4-cyclohexyl-piperidin-1-yl)phenyl]-1,3,4-thiadiazol-2-yl]benzoyl,

R^2 is hydrogen,

R^3 is 2-hydroxy-1-(hydroxymethyl)ethyl,

R^4 is hydrogen,

R^5 is hydroxysulfonyloxy, and

R^6 is hydroxyl.

Claim 16 (New): A process for preparing a polypeptide compound (I) of claim 1, or a salt thereof,

which comprises,

i) reacting a compound (II) of the formula:



(II)

or a salt thereof, with a compound (III) of the formula:

$$R^3{=}O \qquad \text{(III)}$$

or its reactive derivative or a salt thereof, to give a compound (Ia) of the formula:



(Ia)

or a salt thereof, or

ii) reacting a compound (Ia) of the formula:



(Ia)

or a salt thereof, with a compound (IV) of the formula:

R_a^2-OH (IV)

wherein R_a^2 is acyl group,

or its reactive derivative at the carboxy group or a salt thereof, to give a compound (Ib) of the formula:



(Ib)

or a salt thereof, or

iii) subjecting a compound (Ib) of the formula:



(Ib)

or a salt thereof, to elimination reaction of the acyl group, to give a compound (Ia) of the formula:



(Ia)

or a salt thereof, or

iv) reacting a compound (Ic) of the formula:



(Ic)

or a salt thereof, with a compound (V) of the formula:

$$R_a^1\text{-OH} \qquad (V)$$

wherein R_a^1 is acyl group,

or its reactive derivative at the carboxy group or a salt thereof, to give a compound (Id) of the formula:



(Id)

or a salt thereof.

Claim 17 (New): A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.

Claim 18 (New): A method of treating an infectious disease caused by a fungus comprising administering to a human being or an animal subject in need thereof a compound according to claim 1 for a time and under conditions to treat said disease.

Claim 19 (New): A commercial package comprising the pharmaceutical composition of claim 7 and a written matter associated therewith, wherein the written matter states that the pharmaceutical composition can be used for preventing or treating infections disease.

Claim 20 (New): An article of manufacture, comprising packaging material and the compound (I) identified in claim 1 contained within said packaging material, wherein said the compound (I) is therapeutically effective for preventing or treating infectious diseases, and wherein said packaging material comprises a label or a written material which indicates that said compound (I) can be used for preventing or treating infectious diseases.

DISCUSSION OF THE AMENDMENT

Each of Claims 2-5 has been amended by replacing "A" with --The--. Claims 6-12 have been canceled. New Claims 13-20 have been added. Claim 13 is supported by, and limits, Claim 4. Claim 14 is supported by Example 9. Claim 15 is supported by Example 95. Claim 16 is based on, and supported by, Claim 6, but omits the term "or its reactive derivative at the amino group," and superfluous references to ". . . is defined in Claim 1" or ". . . defined above." Claim 17 is identical to original Claim 7. Claim 18 is drawn to a method of treating an infectious disease caused by a fungus comprising administering to a human being or an animal subject in need thereof a compound according to Claim 1 for a time and under conditions to treat said disease, as supported in the specification at page 1, lines 18-31 and page 30, line 21ff. Claims 19 and 20 are otherwise identical to original Claims 11 and 12, respectively, but omit the term "or should".

No new matter is believed to have been added by the above amendment. Claims 1-5 and 13-20 are now pending in the application.